🔴 HCW Biologics is trading 8.76% down in pre-market after shareholders filed to resell 1.24 million shares

HCW Biologics is trading 8.76% down in pre-market at $2.29 after existing shareholders filed to potentially resell up to 1,237,364 shares.

• The company is not issuing these shares and would receive no proceeds; the filing creates a potential supply overhang.
• The decline follows a 14.63% drop during the September 8 session, despite its Akron Biotech distribution agreement for HCW11-006.
• The agreement included prepayment commitments and commercialization for CAR-T manufacturing applications.